Jardiance Cost in Massachusetts 2026: Prices, Insurance, Medicaid, and Compounded Alternatives

What Is the Retail Price of Jardiance in Massachusetts in 2026?

The manufacturer list price for Jardiance sits at roughly $680 per month in 2026, and Massachusetts retail pharmacies generally mirror that figure for uninsured cash-pay customers. Prices vary by chain. CVS, Walgreens, and independent pharmacies across Boston, Springfield, and Worcester all quote figures in the $650-$700 range for a 30-count supply of either the 10 mg or 25 mg tablet.

That number does not reflect what most patients pay. Insurance, assistance programs, and pharmacy discount tools each reduce out-of-pocket exposure substantially. GoodRx and similar discount aggregators occasionally show prices near $550-$580 at select Massachusetts pharmacies, but those coupons cannot be combined with insurance and disqualify the purchase from counting toward your deductible.

Boehringer Ingelheim and Eli Lilly co-market Jardiance. The drug received FDA approval for type 2 diabetes in 2014, for heart failure with reduced ejection fraction in 2021, and for chronic kidney disease (CKD) in 2023 [1]. Each indication expansion has kept demand and therefore pricing pressure high. The FDA label remains available for verification [2].

The EMPA-REG OUTCOME trial (N=7,020) demonstrated that empagliflozin 10 mg or 25 mg reduced the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke by 14% relative to placebo (hazard ratio 0.86 to 95% CI 0.74-0.99, P<0.001 for noninferiority; P=0.04 for superiority) and cut cardiovascular mortality by 38% [3]. That outcome data is a primary reason payers treat Jardiance as a medically necessary drug rather than a lifestyle medication, which matters for Massachusetts coverage decisions.

The EMPEROR-Preserved trial (N=5,988) further showed empagliflozin reduced the risk of cardiovascular death or hospitalization for heart failure by 21% in patients with heart failure with preserved ejection fraction (HR 0.79 to 95% CI 0.69-0.90, P<0.001) [4]. EMPA-KIDNEY (N=6,609) then showed a 28% relative risk reduction in the composite of kidney disease progression or cardiovascular death compared with placebo (HR 0.72 to 95% CI 0.64-0.82, P<0.001) [5].

Does MassHealth (Massachusetts Medicaid) Cover Jardiance?

MassHealth covers Jardiance, but prior authorization (PA) is required. Approval is most straightforward for members with a documented diagnosis of type 2 diabetes, heart failure, or CKD, all three of which are FDA-approved indications backed by outcomes data [1][3][5]. Prescribers submit the PA through the MassHealth PA portal; typical turnaround is 3-5 business days.

The MassHealth Drug List (formulary) classifies empagliflozin as a preferred SGLT2 inhibitor for covered members with qualifying diagnoses. Dapagliflozin (Farxiga) occupies a similar tier, so expect a clinical rationale if switching between agents. The MassHealth member copay after approval is nominal, typically $3.65 for generic-equivalent-tier drugs or up to $8 for brand-tier medications, depending on plan type [6].

Members enrolled in a MassHealth-managed care organization (MCO) such as Tufts Health Together or Boston Medical Center HealthNet Plan follow that MCO's specific PA criteria, which may differ slightly from the fee-for-service standard. Always confirm formulary tier with the specific MCO before submitting the PA.

Patients who do not meet PA criteria because they have pre-diabetes or use empagliflozin off-label for weight management will generally be denied. In those cases, a compounded formulation or a manufacturer savings program becomes the next route.

The American Diabetes Association 2024 Standards of Care state: "In patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk, an SGLT2 inhibitor with demonstrated cardiovascular benefit is recommended to reduce the risk of major adverse cardiovascular events and/or heart failure hospitalization" [7]. That language directly supports MassHealth PA approval for eligible members.

How Does Commercial Insurance Cover Jardiance in Massachusetts?

Commercial plans sold through the Massachusetts Health Connector, employer groups, and the ACA marketplace tier Jardiance differently. Most large carriers, including Blue Cross Blue Shield of Massachusetts, Harvard Pilgrim Health Care, Tufts Health Plan, and Mass General Brigham Health Plan, place empagliflozin on Tier 3 (preferred brand) or Tier 4 (non-preferred brand).

A Tier 3 placement typically means a copay of $50-$80 per 30-day fill after the deductible is met. Before the deductible is satisfied, patients pay the negotiated rate, which usually sits between $250 and $420 depending on the plan's pharmacy benefit manager contract. High-deductible health plans (HDHPs) common among Massachusetts small employers can leave patients paying $600 or more per fill until the deductible resets.

The ACA requires plans sold on the Health Connector to cover at least one SGLT2 inhibitor at the specialty or preferred brand tier for diabetes, but the specific drug and tier vary by carrier year to year. Check the Summary of Benefits and Coverage document for your 2026 plan year.

Step therapy remains common. BCBS of Massachusetts and several other carriers require a trial of metformin and at least one generic diabetes drug before authorizing Jardiance at preferred-tier cost [8]. Prescribers can request a step-therapy exception by documenting contraindications or prior treatment failure. For heart failure or CKD indications, step-therapy barriers are less common because no generic SGLT2 inhibitor exists yet.

What Is the Boehringer Ingelheim / Lilly Savings Card?

The Jardiance savings card (also called the Lilly Insulin Value Program or the Boehringer Ingelheim Cares Foundation Patient Assistance Program) works differently depending on income and insurance status. Commercially insured patients who meet eligibility criteria may pay as little as $10 per month for a 30-day supply. The card covers the gap between insurance cost-sharing and the $10 target, up to a defined monthly maximum benefit.

Key restrictions apply. The card is not valid for patients on federal or state government insurance, including Medicare Part D and Medicaid. Massachusetts residents enrolled in MassHealth or Medicare cannot use the commercial savings card. Government Anti-Kickback Statute regulations prohibit it [9].

To activate the card, patients visit the Jardiance website or ask their prescriber or pharmacist. The program runs continuously but Boehringer Ingelheim can modify terms annually. Patients should verify current eligibility at the time of enrollment.

For uninsured patients, Boehringer Ingelheim's patient assistance program offers free or reduced-cost Jardiance to individuals below 400% of the federal poverty level. In 2026 to 400% FPL for a single person equals roughly $58,000 per year. The application requires income documentation and is processed in approximately 2-3 weeks.

Is Compounded Empagliflozin Legal in Massachusetts?

Compounded empagliflozin is legal in Massachusetts when prepared by a state-licensed 503A compounding pharmacy operating under a valid patient-specific prescription from a licensed prescriber [10]. The 503A designation refers to Section 503A of the Federal Food, Drug, and Cosmetic Act, which governs traditional compounding pharmacies that prepare medications for individual patients.

Massachusetts Board of Pharmacy licenses and inspects 503A pharmacies in the state. The compounder must use pharmaceutical-grade empagliflozin API (active pharmaceutical ingredient) and follow USP compounding standards [11]. The finished product is not FDA-approved, so the pharmacist and prescriber share clinical responsibility for quality verification.

Cost is the primary driver of patient interest. Compounded empagliflozin from a licensed 503A pharmacy in Massachusetts typically costs substantially less than the $680 brand-name price, with some pharmacies quoting $60-$150 per month depending on formulation and dose. Oral capsule and oral solution formulations are most common.

One important caveat: FDA has not placed empagliflozin on its Section 503B "bulk drug substances" list, meaning 503B outsourcing facilities (which can compound without patient-specific prescriptions) cannot legally compound empagliflozin for office use or large-scale distribution. The 503A route requires a prescription written for a specific patient. Any pharmacy offering bulk-compounded empagliflozin without a patient-specific prescription is operating outside federal law [10].

The HealthRX clinical team uses a structured decision framework to guide Massachusetts patients choosing between brand Jardiance, MassHealth-covered Jardiance, and compounded empagliflozin:

1. Insured with commercial plan: Exhaust savings card first. If copay remains above $80/month after card, request a formulary exception citing EMPA-REG OUTCOME cardiovascular outcome data [3].
2. MassHealth-eligible: File PA for qualifying diagnosis. Approval results in near-zero copay.
3. Medicare Part D: Use the $2,000 annual out-of-pocket cap that took effect January 1, 2025 under the Inflation Reduction Act; Jardiance should fall within that cap by mid-year for most beneficiaries [9].
4. Uninsured, income <400% FPL: Apply to Boehringer Ingelheim patient assistance before considering compounding.
5. Uninsured, income above threshold, or cash-pay preference: Compounded empagliflozin from a licensed Massachusetts 503A pharmacy is a legal and cost-effective alternative, provided the prescriber documents clinical rationale.

Can I Get Jardiance via Telehealth in Massachusetts?

Yes. Massachusetts law permits telehealth prescribing of empagliflozin with no geographic restriction on the patient's location within the state. The prescriber must hold a valid Massachusetts medical license, complete an appropriate clinical evaluation (including review of relevant labs such as eGFR and HbA1c), and establish a valid prescriber-patient relationship [12].

The Massachusetts Board of Registration in Medicine has confirmed that telehealth visits satisfying these criteria meet the standard for prescribing controlled and non-controlled medications. Jardiance is not a controlled substance, which simplifies the telehealth pathway considerably compared to, for example, testosterone or Schedule IV medications.

Telehealth platforms operating in Massachusetts, including HealthRX, typically require the patient to share recent labs before a prescriber will initiate empagliflozin. The FDA label specifies that empagliflozin should not be initiated in patients with eGFR <30 mL/min/1.73 m² and should be used with caution for eGFR 30-45 [2]. A prescriber reviewing labs via telehealth can apply those same clinical thresholds. eGFR and urine albumin-to-creatinine ratio are the two most relevant values.

The DECLARE-TIMI 58 trial (N=17,160) evaluated dapagliflozin (a closely related SGLT2 inhibitor) and showed a 17% relative reduction in hospitalization for heart failure, reinforcing that the class effect seen in EMPA-REG extends across agents [13]. Prescribers conducting telehealth evaluations should document the specific indication (diabetes vs. heart failure vs. CKD) because dosing and monitoring differ across indications.

How Does Empagliflozin Work and Why Does the Clinical Evidence Matter for Coverage?

Empagliflozin blocks the sodium-glucose cotransporter-2 (SGLT2) in the proximal tubule of the kidney, reducing renal glucose reabsorption and increasing urinary glucose excretion. This mechanism lowers blood glucose, body weight, and systolic blood pressure without causing insulin-dependent hypoglycemia [2].

The HbA1c reduction with empagliflozin 10 mg averages 0.6-0.8 percentage points from baseline in controlled trials [3]. That is modest compared with some agents, but the cardiovascular and renal outcomes drive prescribing decisions more than glycemic control alone.

The 2023 ADA/EASD consensus on management of hyperglycemia in type 2 diabetes states: "For patients with type 2 diabetes and chronic kidney disease, an SGLT2 inhibitor is recommended to reduce the risk of CKD progression and cardiovascular events, irrespective of HbA1c" [7]. This position, echoed by the 2024 KDIGO guidelines [14], means that Massachusetts prescribers have authoritative backing to prescribe empagliflozin for CKD even when diabetes is well-controlled.

The EMPA-KIDNEY trial specifically enrolled patients with eGFR as low as 20 mL/min/1.73 m², and the 28% relative risk reduction held across subgroups [5]. That finding prompted the FDA label update allowing use down to eGFR 20 for the CKD indication [2].

Genital mycotic infections occur in approximately 5-6% of patients on empagliflozin vs. 1-2% on placebo based on pooled trial data, with higher rates in women [3]. Diabetic ketoacidosis (DKA), though rare in type 2 diabetes, requires sick-day management counseling. Prescribers should instruct patients to hold empagliflozin 3 days before elective surgery or during prolonged fasting [2].

What Is the Cheapest Way to Get Jardiance in Massachusetts?

The lowest realistic monthly cost for each patient category in Massachusetts:

MassHealth member with qualifying diagnosis: $3.65-$8 after approved PA. This is the lowest-cost route for eligible patients.

Commercially insured with savings card: $10/month if the card covers the gap. Activate the savings card through Boehringer Ingelheim's website before the first fill.

Medicare Part D (2026): Under the Inflation Reduction Act's $2,000 annual cap, most Part D beneficiaries will exhaust their exposure by mid-year. Monthly cost in the initial coverage phase varies; the catastrophic cap eliminates further cost after $2,000 [9].

Uninsured, income below 400% FPL: Patient assistance program from Boehringer Ingelheim provides the drug at no cost.

Uninsured, income above threshold: Compounded empagliflozin from a licensed Massachusetts 503A pharmacy, typically $60-$150/month, represents the most affordable legal option.

GoodRx coupons at select pharmacies may reduce cash price to $550-$580 but cannot stack with insurance. The NADAC (National Average Drug Acquisition Cost) for empagliflozin as of early 2026 reflects the brand-only market, since no FDA-approved generic empagliflozin has launched in the United States [15].

Are There Massachusetts-Specific Jardiance Discount Programs?

Beyond the manufacturer savings card, Massachusetts offers several state-level resources. The Health Safety Net (HSN) program covers uninsured and underinsured Massachusetts residents who do not qualify for MassHealth. HSN may cover Jardiance for qualifying diagnoses at low or no cost. Eligibility is income-based, and enrollment occurs through the patient's treating hospital or community health center.

The Massachusetts Prescription Advantage program assists seniors and disabled residents with Medicare drug costs, including specialty drug cost-sharing for drugs on the Medicare Part D formulary. Prescription Advantage supplements Part D by covering copays for members below the income threshold [6].

Community health centers across Massachusetts, including Fenway Health, DotHouse Health, and Greater Lawrence Family Health Center, participate in the 340B Drug Pricing Program. Under 340B, qualifying patients can access Jardiance at acquisition prices far below retail, sometimes as low as $50-$100/month [16]. Eligibility requires that the patient receive care at a 340B-covered entity and meet program criteria.

The Massachusetts Health Connector also publishes an annual drug cost transparency report that lists average pharmacy spending by drug class; SGLT2 inhibitors appear as one of the faster-growing cost categories in the 2024-2025 report, reflecting expanded indications and prescribing volume growth of approximately 22% year over year [17].

Monitoring Requirements That Affect Cost Planning

Patients starting empagliflozin in Massachusetts should budget for monitoring labs in addition to the drug cost itself. The FDA label and ADA guidelines recommend checking eGFR and electrolytes at baseline, at 3 months after initiation, and then annually [2][7]. For patients with CKD (eGFR 20-60), more frequent monitoring, every 3-6 months, is appropriate.

Annual HbA1c testing (twice-yearly if not at goal) adds to the total cost of care, though most insurance plans cover this as preventive care without a copay under ACA requirements. Urine albumin-to-creatinine ratio (UACR) monitoring is recommended for CKD patients; EMPA-KIDNEY used UACR above 200 mg/g as an enrollment criterion [5].

The SGLT2 inhibitor class requires sick-day protocol education. Patients should be counseled to hold empagliflozin during acute illness, fasting over 24 hours, or perioperative periods to reduce DKA risk. This counseling visit is typically covered under standard diabetes management billing codes (CPT 99213-99214 or equivalent telehealth codes) [2].